Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Random

Display 30 Products per page

Acute Myelogenous Leukemia (AML) KOL Interview

€564.08

Datamonitor interviewed three oncology specialists to determine the physicians’ views on marketed and pipeline therapies for Acute Myelogenous Leukemia. Two physicians were based in the US (Greater Midwest and Greater Boston areas) and one in the UK. The three interviews were combined into a single report.
August 19, 2016
Find out more
Mavenclad
Read More
Mavenclad contains cladribine, a small molecule that suppresses the immune system by selectively targeting lymphocytes, which are cells that seem to be major players in MS pathological mechanisms.
November 24, 2017
Find out more
Orbactiv
Read More
Orbactiv is a broad-spectrum antibiotic mainly targeting inpatient settings. The drug is a semisynthetic lipoglycopeptide that inhibits bacterial cell wall synthesis by blocking peptidoglycan biosynthesis.
September 10, 2014
Find out more
U.S. Benign Uterine Conditions Therapy Systems Market

€3,531.38

This report presents an overview of the most common types of treatment for the benign uterine conditions of menorrhagia and uterine fibroids/polyps; among these therapies are dilation and curettage, hysterectomy, hysteroscopy, and myomectomy. Market and competitive analyses for the medical devices used in these treatments also are presented.

May 1, 2013
Find out more
2017 Biomedtracker / Meddevicetracker / Datamonitor Healthcare Post-ESC Report

€4,473.08

The European Society of Cardiology (ESC) Congress 2017 was held in Barcelona, Spain from 26–30 August.
September 14, 2017
Find out more
Xadago
Read More
Xadago (safinamide; Newron Pharmaceuticals/US WorldMeds/Zambon/Meiji Seika Pharma) has a novel dual mechanism of action, based on the enhancement of the dopaminergic function through the reversible inhibition of monoamine oxidase B (MAO-B) and inhibition of excessive glutamate release by blocking the activity of the voltage-dependent sodium channels.
June 21, 2018
Find out more
Big Pharma Diversification Strategies

€2,820.39

Pressures ranging from continually declining revenues as a result of generics and impending biosimilars launches, to slow R&D productivity and market access restrictions could cause the Big Pharma peer set to evaluate business opportunities beyond pharmaceuticals.
March 4, 2018
Find out more
Market Spotlight: Axial Spondyloarthritis (axSpA)

€1,241.16

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
September 23, 2021
Find out more
Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #2

€564.08

This interview provides a thorough description of hepatocellular carcinoma (HCC) treatment in the US. All targeted therapies available for HCC treatment are discussed, as well as a discussion of Phase III pipeline drugs and the potential impact these therapies would have if they gain approval.
February 6, 2019
Find out more
India Pharmaceutical Market Dynamics

€2,820.39

India is one of the most important emerging pharmaceutical markets, and the market is forecast to more than double between 2011 and 2017, growing at a compound annual growth rate of 16.1%.
November 2, 2016
Find out more
Datamonitor Healthcare Ulcerative Colitis KOL Interviews

€564.08

Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC.
August 18, 2017
Find out more
Datamonitor Meningococcal Vaccines KOL Interview

€564.08

Datamonitor interviewed an infectious diseases specialist based in the US Greater Washington DC area to determine this physician’s views on marketed and pipeline meningococcal vaccines.
July 12, 2016
Find out more
MDS/AML KOL Interview

€564.08

Highlights More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects. Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may […]
April 9, 2015
Find out more
US Neurointerventional Devices Market, September 2016

€4,473.08

Neurointerventional radiology/surgery, or neurovascular intervention, is a relatively new medical specialty employing minimally invasive endovascular techniques to treat vascular diseases of the brain.
September 21, 2016
Find out more
Geodon
Read More
Geodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer.
April 9, 2018
Find out more
Schizophrenia and Bipolar Disorder Payer Interview – US, South

€564.08

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning schizophrenia and bipolar disorder, with a focus on oral antipsychotics and long-acting injectables.
April 28, 2021
Find out more
Rituxan
Read More
Rituxan (rituximab; Roche/Biogen/Chugai/Zenyaku Kogyo) is a chimeric monoclonal antibody that binds to the cluster of differentiation (CD)20 antigen, which regulates cell cycle initiation and may function as a calcium ion channel. CD20 is not found on normal plasma cells or normal tissue, but is expressed on over 90% of B-cell non-Hodgkin’s lymphomas (NHLs).
January 31, 2019
Find out more
Rixubis
Read More
Developed by Baxalta (which was then acquired by Shire), Rixubis was only the second recombinant factor IX (rfIX) therapy approved for hemophilia B, and the first to be indicated for routine prophylaxis treatment in adults upon its 2013 approval.
May 4, 2018
Find out more
Tymlos
Read More
Tymlos (abaloparatide; Radius Health) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH). Endogenous PTHrP plays a central role in the regulation of endochondral bone development, with knockout mice not surviving past birth due to lack of proper bone development.
March 9, 2018
Find out more
Alzheimer’s Disease KOL Interview – UK

€564.08

This interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in the UK. We also discuss current and potential treatment options, as well as unmet needs in Alzheimer’s disease.
January 20, 2019
Find out more
Zelboraf
Read More
Zelboraf (vemurafenib; Roche/Chugai/Daiichi Sankyo) is an orally available agent that selectively targets the BRAF mutation. BRAF is part of the mitogen-activated protein kinase (MAPK) signal transduction pathway, which is critical in tumor cell proliferation.
May 23, 2018
Find out more
Alpelisib
Read More
Alpelisib is a p110-alpha isoform-specific PI3K inhibitor. PI3K signaling plays a fundamental role in tumorigenesis, governing cell proliferation, survival, and motility, as well as angiogenesis.
February 5, 2016
Find out more
Hemophilia Pricing, Reimbursement, and Access

€2,820.39

Over the last two decades, clinical care of hemophilia has improved significantly, extending the life expectancy for this patient population closer to that of the general population. The emergence of virally inactivated plasma-derived clotting factors and then of recombinant clotting factor replacement therapy in the 1980s has revolutionized care for these patients.
January 18, 2017
Find out more
United Kingdom, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure

€1,878.69

This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in the United Kingdom (U.K.); incidence and prevalence figures are compared with those of the Benelux countries
December 3, 2012
Find out more
Prostate Cancer: Market Access Pricing & Reimbursement

€2,820.39

The prostate cancer market has become saturated in the metastatic castration-resistant prostate cancer (CRPC) setting; the approval of second-generation antiandrogens, radiotherapies, and chemotherapies has resulted in a great deal of development targeting earlier stages of the disease.
June 1, 2018
Find out more
Germany, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure

€1,878.69

This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in Germany; incidence and prevalence figures are compared with those of the Benelux countries
December 3, 2012
Find out more
Market Spotlight: Norovirus

€1,241.16

This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and an epidemiological overview.
December 2, 2021
Find out more
Market Spotlight: Migraine

€1,241.16

This Market Spotlight report covers the migraine market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
August 17, 2020
Find out more
Gilenya
Read More
Gilenya is a synthetic derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb isaria sinclarii which acts as a potent agonist at four of the S1P receptors (S1P1, S1P3, S1P4, and S1P5).
November 24, 2017
Find out more
Torisel
Read More
Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.
March 6, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *